Evidence for Cognitive Aging in Midlife Women: Study of Women’s Health Across the Nation

Arun S. Karlamangla1*, Margie E. Lachman2, WeiJuan Han1, MeiHua Huang1, Gail A. Greendale1

1 Division of Geriatrics, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America, 2 Department of Psychology, Brandeis University, Waltham, Massachusetts, United States of America

* akarlamangla@mednet.ucla.edu

Abstract

Although cross-sectional studies suggest that cognitive aging starts in midlife, few longitudinal studies have documented within-individual declines in cognitive performance before the seventh decade. Learning from repeat testing, or practice effects, can mask the decline in younger cohorts. In women, the menopause transition also affects test performance and can confound estimates of underlying decline. We designed this study to determine if, after controlling for practice effects, the menopause transition, and the symptoms associated with it, there is evidence of cognitive aging in midlife women. We used data from a longitudinal observational study in 2,124 participants from the Study of Women’s Health Across the Nation. Outcomes examined were scores on annual tests of processing speed, verbal episodic memory (immediate and delayed), and working memory. To reduce the impact of practice effects and of the menopause transition, we used the third cognition testing visit as the baseline. Average age at this baseline was 54 years, and the majority of the women were postmenopausal; half the cohort was 2 or more years beyond the final menstrual period. There were 7,185 cognition assessments with median follow-up time of 6.5 years. In mixed effects regression, adjusted for practice effects, retention, menopause symptoms (depressive, anxiety, vasomotor, and sleep disturbance), and covariates, scores on 2 of 4 cognition tests declined. Mean decline in cognitive speed was 0.28 per year (95% confidence interval [CI] 0.20 to 0.36) or 4.9% in 10 years, and mean decline in verbal episodic memory (delayed testing) was 0.02 per year (95% CI: 0.00 to 0.03) or 2% in 10 years. Our results provide strong, longitudinal evidence of cognitive aging in midlife women, with substantial within-woman declines in processing speed and memory. Further research is needed to identify factors that influence decline rates and to develop interventions that slow cognitive aging.
Introduction

Although decline in cognitive functioning is common in older ages [1,2], there is controversy about whether there is significant decline in cognitive abilities in midlife. Inverse associations between age and cognitive functioning have been seen in cross-sectional analyses of data from middle-aged adults [3,4]; yet within-person longitudinal declines in cognitive performance have not been consistently documented in those under 60 years of age [5,6]. One large study that assessed cognitive performance 3 times over 10 years, did demonstrate longitudinal declines in cognitive performance in midlife, albeit at a slower rate than that of older adults [7].

Yet, in midlife women going through the menopause transition (MT), at least 2 cohorts found no evidence of cognitive aging; instead they documented significant *improvements* in performance over multiple years [8,9]. Similar *improvements* in cognitive performance in midlife have been documented in the Baltimore Longitudinal Study of Aging, and attributed to learning or practice effects from repeat testing [10]. The phenomenon of learning from repeat testing has long been recognized as hampering the estimation of underlying longitudinal change in cognitive performance, and is thought to lead to underestimation—even masking—of true decline [4,6,10,11,12].

Practice effects are largest at first re-testing and diminish significantly with further re-testing [13,14]. We therefore, undertook an analysis of longitudinal cognitive performance data in midlife women from the Study of Women’s Health Across the Nation (SWAN), after excluding data from SWAN’s first 2 cognition testing visits to reduce the impact of practice effects. It has also been suggested that the MT and associated symptoms may impair performance [8,14,15]; both may have confounded previous studies that failed to find evidence of cognitive aging in midlife women. The majority of the SWAN cohort was post menopausal at 3rd cognition testing; thus commencing analysis at 3rd testing reduces effects of the MT on estimates of cognitive performance trajectories. We hypothesized that, after largely eliminating practice effects by initiating our analysis at the 3rd third testing occasion, and explicitly controlling for the MT and associated symptoms, midlife women would indeed show gradual declines in cognitive performance.

Methods

SWAN is a community-based, longitudinal study of midlife women. Entry requirements were: 42 to 52 years of age; intact uterus; at least one ovary; no estrogen use; and at least one menstrual period in the 3 months prior. Seven study sites together recruited 3302 women [16]; the baseline visit occurred in 1996/97, and participants were followed annually thereafter. SWAN participants provided written informed consent, and approval was obtained from Institutional Review Boards at each of the seven SWAN clinical sites and the SWAN coordinating center—Massachusetts General Hospital, Boston, MA; Rush University Medical Center, Chicago, IL; University of Michigan, Ann Arbor, MI; University of California, Los Angeles, CA; Albert Einstein Medical College, New York, NY; Kaiser Permanente Northern California, Oakland, CA; University of California, Davis, CA; and University of Pittsburgh, Pittsburgh, PA. Cognition testing was first administered at the 4th follow-up to 2709 women, and repeated in 6th and subsequent visits up to the 12th follow-up, except that only half the cohort was tested in the 8th follow-up and the remainder in the 9th, and there was no cognition testing in the 11th follow-up.

Study Sample

Of the 2709 women in the SWAN cognition cohort, 2168 (80%) had testing at 3 or more visits—an inclusion criterion for this analysis, which used the 3rd cognition testing as baseline.
Because only 21 (<1%) were from the Hudson County (New Jersey) site, they were excluded; an additional 23 were excluded because of a stroke before their 3rd test, leaving a sample of 2124. Because cognitive aging may accelerate after the menopause [17], we created a subsample of 1224 women whose date of final menstrual period (FMP) was known; FMP date may be unknowable due to interim hysterectomy and/or use of exogenous sex hormones.

Measurements

Outcomes. Cognitive processing speed was assessed with the the symbol digit modalities test (SDMT), in which participants match numbers to symbols in a specified time period [18]; score range, 0–110. Verbal episodic memory was evaluated using the East Boston Memory test (EBMT) [19]: Respondents recall story elements from a paragraph read to them, immediately and after ~10 minutes delay; score range, 0–12. Working memory, the ability to manipulate information held in memory, was assessed by digit span backwards (DSB) [20]: Participants repeat strings of single-digit numbers backwards, with 2 trials at each string length, increasing from 2 to 7, stopped after errors in both trials at a string length, and scored as the number of correct trials (range, 0–12).

Covariates. At SWAN baseline, questionnaires collected age, race/ethnicity, and education. Annually administered questionnaires assessed financial hardship (difficulty paying for basics), diabetes mellitus, sex hormone use, interim hysterectomy and/or bilateral oophorectomy, MT stage (premenopausal: no change in menses regularity, early perimenopausal: menses within the prior 3 months but less predictable, late perimenopausal: > 3 months but < 12 months of amenorrhea, postmenopausal: ≥12 months without menses, and indeterminate because of premenopausal hysterectomy or use of sex steroid hormones before the MT is completed), and FMP date. The Center for Epidemiologic Studies Depression (CES-D) Scale quantified depressive symptoms [21], and coded present if in the top quartile (≥13). Anxiety symptoms were assessed using the SWAN anxiety score [22], and coded present if in the top quartile (≥7). Sleep disturbance was assessed using an abbreviated Pittsburgh Sleep Quality Index, and coded present if either difficulty falling asleep, waking up several times, or waking up earlier than planned with inability to fall asleep again were reported for ≥3 nights per week [23]. Vasomotor symptoms were coded present if any of hot flashes, cold sweats, or night sweats occurred ≥6 days per week [22].

Statistical Analysis

After excluding scores from the first 2 cognition testing occasions, we examined LOESS-smoothed plots of cognition scores as a function of ‘time from FMP’ (negative for dates before the FMP and positive for dates after; a proxy for ovarian aging) and ‘time elapsed since the 3rd cognition testing’ (a measure of chronological aging). Time from FMP more closely captures biological aging in a midlife woman, because of the large changes around the FMP not only in sex hormone levels but also in multiple other physiological markers [24,25,26]. At least one prior study found that cognitive aging accelerates after the menopause [17].

The LOESS plots showed steady declines in the mean values of each of the 4 cognition scores as time from FMP increased (SDMT: Fig 1, EBMT-Delayed: Fig 2, EBMT-Immediate and DSB: not shown). In contrast, the LOESS plots against ‘time since 3rd testing occasion’ showed gradual decline only in SDMT (Fig 3), and not in the other scores (data not shown), and revealed a persistent learning/practice effect from the 3rd to 4th testing in all scores.

We fit linear growth curves to the repeated measurements of each cognition score as function of time from FMP, allowing for a residual practice/learning effect from the 3rd to 4th testing, and censoring observations after an incident stroke. We used linear mixed effects
regression with a random intercept at the participant level to account for clustering of repeated observations from the same woman. Covariates, chosen for known or hypothesized relation to cognitive performance, were modeled as fixed effects on the level (intercept), and included the following time-fixed variables: age at FMP, education (≤ high school, some college,
baccauleurate, post-graduate), race/ethnicity (Black, Chinese, Japanese White), testing language (English, Cantonese Chinese, Japanese), difficulty paying for basics (no hardship, somewhat hard, very hard, refused), use of sex steroids prior to the 3rd cognition testing (yes/no), and the total number of cognition assessments per participant (proxy for characteristics that affect
retention in the study, strongly associated with cognitive performance in older cohorts \cite{1,27,28}). The ‘age at FMP’ covariate controls for differences in cognition performance due to any chronological aging effects prior to the FMP, and isolates biological aging effects related to the MT. Models also included these time-varying covariates: learning/practice effect (0 for the
3rd testing and 1 for ≥4th), use of sex steroid hormone therapy (yes/no), bilateral oophorectomy before natural menopause (yes/no), diabetes (yes/no), and MT-associated symptoms (depressive, anxiety, sleep disturbance, and vasomotor). Analyses were conducted using complete cases (no covariates missing).

To examine the relation between cognitive performance and chronological aging, we ran parallel models that fit linear growth curves to the cognition scores as a function of time since 3rd cognition testing, with all the same covariates except that age at FMP was replaced by age at the 3rd cognition testing (to capture cross-sectional age differences in cognition). We included one additional time-varying covariate, MT stage at the time of testing, to remove effects of the MT, and isolate chronological aging effects. Because this analysis did not require an FMP date, it was done in the larger sample of 2124 participants who met study entry criteria (except not requiring known date of FMP).

**Results**

The study sample was similar to the SWAN cognition cohort (Table 1). At the 3rd cognition testing (baseline for this analysis), median age was 54 years (interquartile range 52 to 56), and the majority of the women were post-menopausal. Nearly half were Caucasian, and the majority were tested in English. About a quarter had post-graduate education. The FMP subsample was very similar to the study sample (Table 1); at the baseline for this analysis, half of these women were at least 2 years past the FMP.

In the study sample and FMP subsample, the mean number of cognition testing occasions available for analysis was 3.4, but the majority of women participated in all 4 cognitive visits (at the 7th, either 8th or 9th, 10th, and 12th follow-ups). There was a total of 7,185 repeated assessments in the study sample, and 4,163 in the FMP subsample. Some women did not complete all 4 cognition tests at every testing occasion: in the study sample, there were 31 missing SDMT scores, 2 missing EBMT immediate recall, 6 missing EBMT delayed recall, and 171 missing DSB scores; corresponding missing numbers in the FMP subsample were 18, 0, 2, and 94. The median length of follow-up was 6.5 years (interquartile range 5.2 to 6.8) in the study sample, and 6.5 years (interquartile range 5.6 to 6.8) in the FMP subsample.

In linear, mixed effects regression in the FMP subsample, adjusted for age at the FMP, practice (learning) from the 3rd to the 4th testing, and retention, SDMT scores decreased on average by 0.27 per year (p < .0001), and EBMT delayed recall scores decreased on average by 0.02 per year (p = 0.01). These declines persisted after additional adjustment for education, race/ethnicity, testing language, clinical site, financial hardship, oophorectomy, sex hormone use, diabetes, and symptoms of depression, anxiety, sleep disturbance, and vasomotor instability, although the decline in EBMT-delayed recall scores became marginally significant (Table 2, ovarian aging model). Between-women difference in SDMT score by age at FMP (0.31 decline per year) was nearly identical in magnitude to the longitudinal aging effect (0.28 decline per year). There were no cross-sectional or longitudinal aging effects seen for the other 2 cognition test scores: EBMT immediate recall and DSB (Table 2).

There were also strong practice effects in SDMT, but not in the other 3 test scores: mean SDMT learning from 3rd to 4th testing was 0.62 (p = 0.01). In addition, there were retention effects seen in 3 of the 4 tests; scores were higher in those who were tested more often: SDMT (p = 0.0001), EBMT delayed recall (p = 0.04) and DSB (p = 0.06).

The second set of models examined test scores as a function of chronological aging—calendar time since the 3rd cognition testing—and yielded similar findings. Adjusted only for age at the 3rd testing, practice from the 3rd to 4th fourth testing, and retention, SDMT scores decreased on average by 0.24 per year (p < .0001). This decline persisted in the fully adjusted
Table 1. Descriptive Statistics for the Study Sample and the FMP Subsample compared to the SWAN Cognition Cohort.

| Participant Characteristics (Number of participants) | Study Sample² (2,124) | FMP Subsample³ (1,224) | SWAN Cognition Cohort⁴ (2,709) |
|-----------------------------------------------------|-----------------------|------------------------|-------------------------------|
| Age at third cognition testing² (years)             | 54.0 (3.0)            | 54.0 (3.0)             | -                             |
| Age at FMP (years)                                  | -                     | 52.0 (2.6)             | -                             |
| Race/ethnicity                                      |                       |                        |                               |
| White                                               | 1045 (49.2%)          | 551 (45.0%)            | 1276 (47.1%)                  |
| Black                                               | 624 (29.4%)           | 376 (30.7%)            | 771 (28.5%)                   |
| Chinese                                             | 214 (10.1%)           | 146 (11.9%)            | 235 (8.7%)                    |
| Japanese                                            | 241 (11.3%)           | 151 (12.3%)            | 258 (9.5%)                    |
| Hispanic                                            | 0                     | 0                      | 169 (6.2%)                    |
| SWAN clinical site                                  |                       |                        |                               |
| Boston, MA                                          | 352 (16.4%)           | 212 (17.3%)            | 397 (14.6%)                   |
| Chicago, IL                                         | 299 (14.1%)           | 184 (15.0%)            | 370 (13.7%)                   |
| Detroit, MI                                          | 382 (18.0%)           | 226 (18.5%)            | 447 (16.5%)                   |
| Los Angeles, CA                                     | 415 (19.5%)           | 223 (18.1%)            | 453 (16.7%)                   |
| Hudson County, NJ                                    | 0                     | 0                      | 248 (9.1%)                    |
| Oakland, CA                                         | 369 (17.4%)           | 231 (18.8%)            | 417 (15.4%)                   |
| Pittsburgh, PA                                       | 307 (14.5%)           | 148 (12.1%)            | 377 (13.9%)                   |
| Education level                                     |                       |                        |                               |
| High school or less                                 | 396 (18.7%)           | 239 (19.7%)            | 606 (22.6%)                   |
| Some college                                        | 681 (32.2%)           | 397 (32.6%)            | 869 (32.3%)                   |
| Baccalaureate                                       | 481 (22.8%)           | 279 (23.0%)            | 568 (21.1%)                   |
| Postgraduate                                        | 555 (26.3%)           | 301 (24.7%)            | 644 (24.0%)                   |
| Menopause transition (MT) stage at time of 3rd cognition testing |                       |                        |                               |
| Premenopause                                        | 38 (1.8%)             | 23 (1.9%)              | -                             |
| Early perimenopause                                 | 461 (21.7%)           | 309 (25.2%)            | -                             |
| Late perimenopause                                  | 196 (9.2%)            | 164 (13.4%)            | -                             |
| Post menopause not taking sex steroids              | 1057 (49.8%)          | 710 (58.0%)            | -                             |
| Postmenopause taking sex steroids                   | 75 (3.5%)             | 18 (1.5%)              | -                             |
| Indeterminate MT stage                              | 295 (13.9%)           | 0 (0.0%)               | -                             |
| Use of sex hormones prior to third testing          | 562 (26.5%)           | 30 (2.5%)              | -                             |
| Financial hardship at third testing                 |                       |                        |                               |
| Not hard paying for basics                          | 1508 (71.0%)          | 842 (68.8%)            | -                             |
| Somewhat hard                                       | 465 (22.0%)           | 296 (24.2%)            | -                             |
| Very hard                                           | 109 (5.1%)            | 64 (5.2%)              | -                             |
| Refused                                             | 42 (1.9%)             | 22 (1.8%)              | -                             |
| Diabetic at 3rd cognition testing                   | 193 (9.1%)            | 116 (9.5%)             | -                             |
| Depressive symptoms 3rd cognition testing           | 448 (21.1%)           | 248 (20.3%)            | -                             |
| Anxiety symptoms at 3rd cognition testing           | 671 (31.6%)           | 370 (30.2%)            | -                             |
| Sleep disturbance 3rd cognition testing             | 627 (29.5%)           | 328 (26.8%)            | -                             |
| Vasomotor symptoms 3rd cognition testing            | 556 (26.2%)           | 312 (25.5%)            | -                             |
| Language of cognition testing                       |                       |                        |                               |
| English                                             | 1945 (91.6%)          | 1101 (90.0%)           | 2372 (87.6%)                  |
| Cantonese Chinese                                   | 88 (4.1%)             | 57 (4.6%)              | 82 (3.0%)                     |
| Japanese                                            | 91 (4.3%)             | 66 (5.4%)              | 102 (3.8%)                    |
| Spanish                                             | 0                     | 0                      | 153 (5.6%)                    |
| Cognition test scores 3rd cognition testing         |                       |                        |                               |
| Symbol Digit Modalities Test                        | 57.3 (11.1)           | 57.2 (11.3)            | -                             |

(Continued)
model (Table 2, chronological aging model). Between-women difference in SDMT score by age at 3rd testing was more than double the longitudinal aging effect: 0.54 vs. 0.25 decline per year (Table 2). There were no longitudinal aging effects seen for the other 3 cognition tests, but there was a cross-sectional age effect on DSB scores (Table 2). As before, there were strong practice (0.60; p = 0.001) and retention effects (p < 0.0001) on SDMT scores. There was also a positive retention effect on EBMT immediate recall (p = 0.02) and EBMT delayed recall (p = 0.0005).

To remove residual confounding by persisting practice effects, we conducted a sensitivity analysis in which we ran the mixed effects models after dropping data from the 3rd cognition occasion.

### Table 1. Participant Characteristics (Number of participants)

| Study Sample | FMP Subsample | SWAN Cognition Cohort |
|--------------|---------------|-----------------------|
| East Boston Memory Test—Immediate | 10.4 (1.7) | 10.3 (1.6) | - |
| East Boston Memory Test—Delayed | 10.2 (1.8) | 10.2 (1.8) | - |
| Digit Span Backwards | 6.88 (2.3) | 6.86 (2.3) | - |
| Number of cognition assessments, starting with 3rd testing occasion | 3.4 (0.9) | 3.4 (0.9) | |

1. Mean (standard deviation) for continuous variables; number (percentage) for categorical variables
2. Women from the SWAN Cognition Cohort who met the requirements for inclusion in the current analysis; the primary reason that women in the SWAN Cognition Cohort were excluded from this study sample was that they had cognition testing on 2 or fewer visits (see Methods).
3. Subset of the study sample for whom the date of the final menstrual period (FMP) was known.
4. SWAN enrolled 3302 women at baseline. The study initiated cognitive performance testing at the 4th follow-up visit. The SWAN Cognition Cohort consists of women who were still participating in SWAN at or after the 4th follow-up and who agreed to undergo cognitive testing.
5. The 3rd administration of SWAN cognitive tests served as the baseline for this analysis.

doi:10.1371/journal.pone.0169008.t001

### Table 2. Adjusted, Annualized Rates of Change in Cognition Test Scores: Results of Linear Mixed Effects Regressions.

| Ovarian Aging Model | Symbol Digit Modalities Test | East Boston Memory Test—Immediate Recall | East Boston Memory Test—Delayed Recall | Digit Span Backwards |
|---------------------|------------------------------|----------------------------------------|----------------------------------------|---------------------|
| **Age at final menstrual period (FMP)** (Between-women differences) | **-0.31 (-0.50, -0.11)** | 0.01 (-0.02, +0.04) | 0.01 (-0.02, +0.04) | **-0.01 (-0.05, +0.03)** |
| **Time since final menstrual period** (Within-woman, longitudinal) | **-0.28 (-0.36, -0.20)** | -0.01 (-0.02, +0.01) | **-0.02 (-0.03, 0.00)** | 0.00 (-0.02, +0.02) |
| **Chronological Aging Model** | **Age at 3rd testing** (Between-women, cross-sectional) | **-0.54 (-0.67, -0.40)** | 0.00 (-0.02, +0.02) | -0.01 (-0.03, +0.01) | **-0.03 (-0.06, 0.00)** |
| **Time since 3rd testing** (Within-woman, longitudinal) | **-0.25 (-0.32, -0.18)** | 0.00 (-0.02, +0.02) | 0.00 (-0.02, +0.01) | 0.00 (-0.02, +0.02) |

1. Annualized slope (95% confidence interval)
2. The ovarian aging model quantifies the change in cognitive test performance in relation to time from FMP (time prior to the FMP takes on a negative value and time after the FMP a positive value—see Methods for details). Model adjusted for age at FMP, practice/learning effects, retention, race/ethnicity, education level, language of testing, financial hardship, use of sex hormones, bilateral oophorectomy, diabetes, depression, anxiety, vasomotor symptoms, sleep disturbance, and study site, using 4,162 observations from 1,223 women (after dropping one observation because of missing covariates).
3. The chronological aging model quantifies the change in cognitive test performance in relation to time elapsed since the 3rd cognition testing (baseline for the current analysis). Model adjusted for age at 3rd testing, practice/learning effects, retention, race/ethnicity, education level, language of testing, financial hardship, use of sex hormones, bilateral oophorectomy, diabetes, depression, anxiety, vasomotor symptoms, sleep disturbance, study site, and menopause transition stage at time of testing, using 7,189 observations from 2,121 women (after dropping 6 observations because of missing covariates).

doi:10.1371/journal.pone.0169008.t002
testing and allowing for a practice effect from 4th to 5th testing. Longitudinal aging estimates from the fully adjusted models were somewhat larger: SDMT declined 0.35 per year (95% confidence interval [CI]: 0.24, 0.46) in the ovarian aging model (2,926 observations from 1,130 women) and 0.25 per year (95% CI: 0.15, 0.36) in the chronological aging model (5,041 observations from 1,963 women).

**Discussion**

As hypothesized, after controlling for practice effects, the MT and MT symptoms, midlife women did show longitudinal declines in cognitive performance, mainly in processing speed. The average, within-woman rate of decline (longitudinal aging effect) in processing speed was essentially identical to the average, between-women difference by age at time of FMP (0.28 per year vs. 0.31 per year). However, as in previous studies [7], cross-sectional differences by chronological age at time of testing were substantially larger than longitudinal aging effects (0.54 per year vs. 0.25 per year), likely because between-women differences in ovarian age were not completely eliminated by controls for MT stage.

Previous studies have found that cognitive processing speed is especially sensitive to early changes [29,30,31]. We found longitudinal declines in both processing speed and verbal memory (delayed recall) in this study. The estimated decline rates translate to a 10-year reduction of approximately 0.25 standard deviations (SD) of the baseline score or 4.9% of the mean baseline score in processing speed, and 0.11 SD of the baseline score or 2.0% of the mean baseline score in delayed recall. These rates are similar to the 10-year longitudinal decline of 3.6% in reasoning score seen in 45–49 year old women in the Whitehall cohort [7]. Consistent with previous work, we also did not see longitudinal declines in immediate recall and working memory; however, more sensitive measures of episodic and working memory might indeed show declines in midlife.

Although there is some evidence that circulating estrogen might protect premenopausal women from cognitive aging [32,33], we did not see a sharp acceleration of cognitive decline during or after the menopause transition (Figs 1 and 2). Instead, the rates of longitudinal decline in SDMT scores were nearly identical regardless of whether time was indexed to the date of the FMP (ovarian aging model) or measured from study baseline (chronological aging model). However, MT-related declines in circulating estradiol level start 2 years before the FMP, and declines in other estrogen-dependent biological systems, such as bone, commence well before the FMP [26,34]. Because 75% of participants in the current analysis were 52 years of age or older at study baseline and the mean age at FMP was 52, the vast majority were “past” the time when an estradiol-related inflection in the cognitive performance trajectory might occur. The likelihood of such an inflection in cognitive performance trajectory prior to the FMP is supported by our finding that between-women differences by age at FMP were smaller than between-women differences by age at time of testing.

As in older cohorts, we also saw a retention effect in this midlife cohort: Cognitive performance was better in women who stayed in the study longer, although attrition was not primarily due to death in this cohort. At least one other study found similar differences by retention in cognitive performance in the 6th decade, but concluded that selective retention did not bias estimates of longitudinal cognitive decline [35].

Limitations of our study include the inability described above to detect initiation or acceleration of cognitive decline at the time that estrogen starts declining, absence of men from the study, and limited generalizability to women not represented in this study, including those who use sex hormones during the MT, who had a hysterectomy without bilateral
oophorectomy prior to natural menopause, who were too ill to participate, from less developed economies, and women from race/ethnicity groups not represented in SWAN.

In conclusion, this study provides good new evidence of cognitive aging in women in midlife, with significant longitudinal declines in both processing speed and verbal memory. Unlike previous longitudinal studies in midlife that were based on 3 or fewer cognition assessments, and could not adequately account for practice effects, we analyzed up to 6 annual or biennial assessments, allowing us to minimize the impact of practice effects and unmask declines. Practice effects are larger in younger, cognitively intact individuals than in older adults [36] and can dominate over the smaller declines in cognitive performance in midlife; more complete elimination of practice effects may show that midlife declines are even steeper.

A decline in processing speed in midlife is not a harbinger of declines in other domains of functioning [37], there are individual differences in cognitive aging, and resilience and compensatory mechanisms can ameliorate the impact of cognitive aging on functioning and well-being [38]. Cognitive aging may also be malleable [39,40]. Further research is needed to determine factors that influence differential rates of decline in cognitive performance with an eye towards developing interventions aimed at slowing cognitive aging.

Acknowledgments
We thank SWAN participants, the investigators and study staff at SWAN clinical sites, central laboratory, and coordinating center, the steering committee chair, and the NIH program officers and staff.

Author Contributions
Conceptualization: ASK MEL GAG.
Data curation: MHH.
Formal analysis: ASK WJH.
Funding acquisition: GAG.
Methodology: ASK.
Project administration: ASK.
Software: WJH.
Supervision: ASK.
Writing – original draft: ASK.
Writing – review & editing: ASK MEL WJH MHH GAG.

References
1. Karlamangla AS, Miller-Martinez D, Aneshensel CS, Wight RG, Seeman TE, and Chodosh J. Trajectories of cognitive function in late life in the United States: Demographic and socioeconomic predictors. *Amer J Epidemiol* 2009; 170(3):331–342.
2. Deary IJ, Corley J, Gow AJ, Harris SE, Houlihan LM, Marioni RE, et al. Age-associated cognitive decline. *British Med Bull* 2009; 92: 135–152.
3. Schroeder DH & Salthouse TA. Age-related effects on cognition between 20 and 50 years of age. *Personality and Individual Differences* 2004; 36: 393–404.
4. Salthouse TA. When does age-related cognitive decline begin? *Neurobiology of Aging* 2009; 30: 507–514 doi: 10.1016/j.neurobiolaging.2008.09.023 PMID: 19231028
5. Hedden T & Gabrieli JD. Insights into the ageing mind: a view from cognitive neuroscience. Nat Rev Neurosci 2004; 5:87–96 doi: 10.1038/nrn1323 PMID: 14735112

6. Rönnlund M, Nyberg L, Backman L, and Nilsson LG. Stability, growth, and decline in adult life span development of declarative memory: Cross-sectional and longitudinal data from a population-based study. Psychology and Aging 2005; 20: 3–18 doi: 10.1037/0882-7974.20.1.3 PMID: 15769210

7. Singh-Manoux A, Kivimäki M, Glymour M, Elbaz A, Berr C, Eebo K, et al. Timing of the onset of cognitive decline: Results from Whitehall II prospective cohort study. BMJ 2012; 344: Early Epub Jan 5, 2012

8. Fuh JL, Wang SJ, Lee SJ, Lu SR, and Juang KD. A longitudinal study of cognition change during early menopausal transition in a rural community. Maturitas 2006; 53(4): 447–453 doi: 10.1016/j.maturitas.2005.07.009 PMID: 16198073

9. Greendale GA, Huang MH, Wight RG, Seeman TE, Luetters C, Avis NE, Johnston J, and Karlamangla AS. Effects of the menopause transition and hormone use on cognitive performance in mid-life women. Neurology 2009; 72: 1850–1857 doi: 10.1212/WNL.0b013e3181a71193 PMID: 19470968

10. Lamar M, Resnick SM, and Zonderman AB. Longitudinal changes in verbal memory in older adults: Distinguishing the effects of age from repeat testing. Neurology 2003: 60:82–86 PMID: 12525723

11. Rabbitt P, Lunn M, Wong D, and Cobain M. Age and ability affect practice gains in longitudinal studies of cognitive change. J Geront Psych Sciences 2008; 63B (4): P235–P240.

12. Salthouse TA. Aging cognition unconfounded by prior test experience. J Gerontology, Series B: Psych Sci Soc Sci 2014 Sep 2: Early Epub;

13. Bartels C, Wegryzn M, Wiedl A, Ackerman V, and Ehrenreich H. Practice effects in healthy adults: A longitudinal study on frequent repetitive cognitive testing. BMC Neuroscience 2010, 11:118 doi: 10.1186/1471-2202-11-118 PMID: 20846444

14. Greendale GA, Wight RG, Huang MH, Avis N, Gold E, Joffe H, Seeman T, Vuje M, and Karlamangla AS. Menopause-associated symptoms and cognitive performance: Results from the Study of Women’s Health Across the Nation. Amer J Epidemiol 2010; 171(11): 1214–1224

15. Mitchell E & Woods N. Midlife women’s attributions about perceived memory changes: Observations from the Seattle Midlife Women’s Health Study. J Womens Health Gend Based Med 2001; 10: 351–362. doi: 10.1089/152460901750269670 PMID: 11445026

16. Sowers MF, Crawford SL, Sternfeld B, Morganstein D, Gold EB, Greendale GA, et al. SWAN: A multi-center, multi-ethnic, community-based cohort study of women and the menopausal transition. In: Lobo RA, Kelsey J, Marcus R, eds. Menopause Biology and Pathobiology. San Diego, CA: Academic Press 2000: 175–88

17. Halbreich Y, Lumley LA, Palter S, Manning C, Gengo F, and Joe SH. Possible acceleration of age effects on cognition following menopause. J Psychiat Res 1995; 29(3): 153–165 PMID: 7473292

18. Smith A. Symbol Digit Modalities Test. Los Angeles, CA: Western Psychological Service, 1982

19. Albert M, Smith LA, Scherr PA, Taylor JO, Evans DA, and Fischbeck HH. Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer’s disease. Int J Neurosci 1991; 57(3–4): 167–78. PMID: 1938160

20. Psychological Corporation. WAIS-III and WMS-III: Technical manual. San Antonio, TX: Psychological Corporation/Harcourt Brace, 1997

21. Radioff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977:385–401.

22. Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women’s Health Across the Nation. Am J Public Health. 2006; 96(7):1226–1235. doi: 10.2105/AJPH.2005.066936 PMID: 16756936

23. Becker PM. Insomnia: prevalence, impact, pathogenesis, differential diagnosis, and evaluation. Psychiatr Clin North Am. 2006; 29(4):855–870. doi: 10.1016/j.psc.2006.08.001 PMID: 17118272

24. Matthews KA, Crawford SL, Chae CU, Everson-Rose SA, Sowers MF, Sternfeld B, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? Journal of the American College of Cardiology 2009; 54 (25): 2366–2373. doi: 10.1016/j. jacc.2009.10.009 PMID: 20882925

25. Janssen I, Powell LH, Crawford S, Lasley B, and Sutton-Tyrrell K. Menopause and the metabolic syndrome: the Study of Women’s Health Across the Nation. Archives of Internal Medicine 2006; 166(14): 1568–1575. doi: 10.1001/archinte.166.14.1568 PMID: 16993170

26. Randolph JF Jr, Zheng H, Sowers MR, Crandall C, Crawford S, Gold EB, et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: Effect of age at the final menstrual period. J Clin Endocrinol Metab 2011, 96(3):746–754. doi: 10.1210/jc.2010-1746 PMID: 21159842
27. Sliwinski MJ, Hofer SM, Hall C, Buschke H, and Lipton RB. Modeling memory decline in older adults: The importance of preclinical dementia, attrition, and chronological age. *Psychol Aging* 2003; 18(4): 658–671. doi: 10.1037/0882-7974.18.4.658 PMID: 14692855

28. Rabbitt P, Lunn M, and Wong D. Death, dropout, and longitudinal measurements of cognitive change in old age. *J Geront Psych Sci* 2008; 63B (5): P271–P278

29. Finkel D, Reynolds CA, McArdle JJ, and Pedersen NL. Age changes in processing speed as a leading indicator of cognitive aging. *Psychology and Aging* 2007; 22: 558–568 doi: 10.1037/0882-7974.22.3.558 PMID: 17874954

30. Salthouse TA. The processing-speed theory of adult age differences in cognition. *Psychological Review* 1996; 103: 403–428. PMID: 8759042

31. Nilsson J, Thomas AJ, O’Brien JT, and Gallagher P. White matter and cognitive decline in aging: A focus on processing speed and variability. *Journal of the International Neuropsychological Society* 2014; 20(3): 262–267

32. Bailey ME, Wang AC, Hao J, Janssen WG, Hara Y, Dumitriu D, et al. Interactive effects of age and estrogen on cortical neurons: implications for cognitive aging. *Neuroscience*, 2011; 191: 148–158. doi: 10.1016/j.neuroscience.2011.05.045 PMID: 21664255

33. Henderson VW. Gonadal hormones and cognitive aging: a midlife perspective. *Women’s Health* 2011; 7(1): 81–93. doi: 10.2217/whe.10.87 PMID: 21175393

34. Greendale GA, Sowers M, Han W, Huang MH, Finkelstein JS, Crandall CJ, Lee JS, and Karlamangla AS. Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women’s Health Across the Nation (SWAN). *J Bone Miner Res*. 2012 Jan; 27 (1):111–8. doi: 10.1002/jbmr.534 PMID: 21976317

35. Salthouse TA. Selectivity of attrition in longitudinal studies of cognitive functioning. *Journals of Gerontology, Series B: Psychological Sciences and Social Sciences* 2014; 69(4): 567–574.

36. Salthouse TA. Frequent assessments may obscure cognitive decline. *Psychological Assessment* 2014, 26(4): 1063–1069. doi: 10.1037/pas0000007 PMID: 24840179

37. Ramscar M, Hendrix P, Shaoul C, Milin P, and Baayen H. The myth of cognitive decline: Non-linear dynamics of lifelong learning. *Topics in Cognitive Science* 2014; 6: 5–42. doi: 10.1111/tops.12078 PMID: 24421073

38. Hahn EA & Lachman ME. Everyday experiences of memory problems and control: The adaptive role of selective optimization with compensation in the context of memory decline. *Aging, Neuropsychology, and Cognition* 2015; 22(1): 25–41

39. Burke SN & Barnes CA. Neural plasticity in the ageing brain. *Nature Reviews Neuroscience* 2006; 7: 30–40. doi: 10.1038/nn1809 PMID: 16371948

40. Lindenberger U. Human cognitive aging: Corriger la fortune? *Science* 2014; 346 (6209): 572–8. doi: 10.1126/science.1254403 PMID: 25359964